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Bioavailability and In-vivo Transdermal Delivery of Haloperidol
Abubakr S. Elgorashi
Abstract:
Background: Sustained blood level with effective therapeutic blood level in 
psychotic patients in the range of usual therapeutic dose is favorable.
Objectives: To investigate where this sustained and effective therapeutic blood 
level and improve in bioavailability could be achieved by using 
haloperidol/transdermal gel formulation.
Materials and Methods:  In-vivo transdermal delivery of haloperidol was 
studied in rabbits comparing transdermal gel formulation containing 1, 8-cineole 
as penetration enhancer and oral tablet. Concentrations of haloperidol in plasma were measured by 
reverse phase HPLC. The pharmacokinetic parameters generated from this study were evaluated 
statistically using one-way analysis of variance (ANOVA).
Result: The results showed that transdermal gel formulation increased rate and extent of absorption 
and improve bioavailability of haloperidol. The plasma concentrations of haloperidol were declined 







,  mean residence time (MRT), mean absorption time (MAT), and total 
clearance (CL
total
) were significantly different p < 0.05, but  volume of distribution (V
d
) did not 
differ significantly p >0.05.The absolute bioavailability from the oral tablet, and the transdermal 
formulation was 38% and 57% respectively and highly significant P < 0.01.
Conclusion: This study suggest that it is possible to achieve significant sustained therapeutic blood 
levels for longer time and also suggest that further human investigations of the transdermal dosage 
are warranted. 
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Pharmacokinetic. 
aloperidol is a neuroleptic  
butyrophenone antipsychotic  used in 
the treatment of schizophrenia acute 
and chronic psychotic syndromes, hyperactive 
conditions in children, abnormal movements 
and confused states, aggressive behavior in 
elderly, hyperactivity, psychomotor agitation 
and restlessness. The drug has also been used 
for schizoaffective disorders, mania, paranoid, 
and tourettes syndrome
1
. This drug is rapidly 
and almost completely absorbed when taken 
orally, (60-70%). But the oral bioavailability 
is about 59% due to extensive first-pass 
metabolism in liver 
2, 3
. 
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Transdermal delivery of drug remains an 
important alternative route for drug 
administration to overcome its poor oral 
bioavailability. It maintains a sustained blood 
levels for longer period of time. Over the last 
years transdermal preparations have been 
developed to be administered via this route. 
Success has been achieved in the 
administration of some drugs
4-7
. The rate of 
release of drug from these transdermal 
delivery systems has determined the 
successfulness of the performance of the 
dosage form. The purpose of this study is to 
assess the pharmacokinetic characteristic of 
haloperidol delivered transdermally via a 
transdermal gel matrix formulation containing 
enhancer   in vivo using rabbits and compare 
that with a commercial oral tablet and 
intravenous injection of haloperidol. 
H
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Materials and Methods
Materials 
Haloperidol and hydroxypropylmethyl 
cellulose (Sigma Chem. Co., St. Louis, MO, 
U. S. A.), propylene glycol, 1,8 cineole, 
glacial acetic acid, acetonitrile and methanol 
(BDH Chemicals Ltd., Poole, UK), Sodium 
hydroxide (E. Merck AG, Dermstadt, 
Germany), (Fluka Ag, Buchs SG, 
Switzerland), Potassium dihydrogen 
phosphate, disodium hydrogen phosphate, 
phosphoric acid, ethanol and triethanolamine 
(Riedel-De-Haen AG, Seelze, Hannover, 
Germany) and methyl paraben (Winlab Ltd, 
Maidenhead, Berkshire, U. K). Acetonitrile 
and Methanol were HPLC grade. All 
chemicals were used as received.
HPLC Analysis of haloperidol
The concentrations of haloperidol samples 
were determined using an HPLC system 
equipped with binary pump model LC- 10 AD 
and the variable wavelength ultraviolet 
detector SPD-10A set at 247 nm. (Shimadzu 
Corporation, Kyoto. Japan), and automatic 
injector (Waters associates Bedford). A 
stainless steel adsorbasphere phenyl column 
(4.6 mm id X 150 mm length) packed with 5 
µm particle size ultrasphere (Alltech 
Associates Inc., IL, U.S.A.) was used as 
analytical column at 30 
o 
C using column 
oven. The mobile phase consisted of 
acetonitrile: methanol: 0.05 M phosphate 
buffer (25: 25: 50% v/v) in addition to 1.0 ml 
triethylamine adjusted to pH 7.10 with 
Phosphoric acid (0.25 ml). The mobile phase 
was degassed by passing it through 0.22-µm 
membrane filter type GV (Millipore, Bedford, 
MA U.S.A.) and pumped isocratically at a 
flow rate of 1.2 ml/ minute. The chart speed 
was 0.30 cm/minutes.
Phase was pumped at flow rate of 1.5 ml 
/minutes. A volume of 50µl was injected for 
all samples.
 Preparation of haloperidol gel 
formulations
Fifty milligrams of haloperidol were 
dissolved in a heated aliquot of propylene 
glycol (about 3 g), containing 20 mg of 
methyl paraben.  Then 1.2 g of HPMC was 
dispersed in a warm aliquot of propylene 
glycol and left in freezer for 1 hour at –20 ˚C, 
after the gel was formed, 1,8-cineole-
propylene glycol solution was added drop 
wise to the gel with continuous stirring 
(0.1gm 1,8-cineole). The pH of he formula 
was adjusted to 7.1 by adding few drops of 
sodium hydroxide, and the final weight was 
adjusted to 10 g with propylene glycol 
containing 10% w/w of 1,8-cineole. 
In-vivo Formulation Studies
In order to gain a full insight into the 
transdermal absorption of haloperidol, in-vivo 
studies in human subject has to be performed. 
However, human studies are costly and time 
consuming due to the necessary safeguards, 
including the approval of clinical protocols 
for human use. Therefore, experimental 
animals are widely used as models for in-vivo 
percutaneous drug absorption despite of the 
fact that animal models differ significantly 
from man in features which affect 
percutaneous absorption such as density of 
hair follicles and sweat glands, thickness and 
nature of stratum cornium, and papillary 
blood supply. Investigators usually utilized 
rabbits as model for cutaneous absorption 
studies. Rabbits are easily handled concerning 
housing, feeding, supply and collecting blood 
samples. Thus, rabbits have been chosen for 




The intravenous solution was prepared 
by dissolving 50 mg of haloperidol in 20-ml 
volumetric flask containing 5mls ethanol and 
5 ml propylene glycol the volume was 
completed to 20 ml by isotonic normal saline 
solution. This procedure was carried out in a 
laminar flow hood under aseptic technique. 
The final solution contains 2.5 mg/ml of 
haloperidol.
Five white male New Zeland rabbits 
weighing 3.5-4.5 kg were utilized in the 
study. The animals were fasted for 18 hours 
before and during the experiment. After 
immobilization of the rabbits in a rabbit 
restrainer, the hair was removed from the ears 
with an animal clipper. One ml of haloperidol 
solution previously prepared containing 2.5 
mg/ml was administered slowly through the 
marginal vein.  Before the drug administration 
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each rabbit was injected with 3000 units of 
heparin to avoid cannular occlusion. Blood 
samples, 1.5 ml each, were collected in 5ml 
heparinized evacuated blood collection tubes 
via iv-catheter (18G X 1¼ inch) inserted into 
the central artery, at 0, 0.08, 0.16, 0.33, 0.50, 
0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0 and 10.0 
hours post injection. Blood samples were 
centrifuged immediately for 10 minutes at 
4000 rpm and plasma were separated by using 
Pasteur pipettes and transferred to Bijue 
bottles and stored at -20 
o
C before analysis. 
0.25 ml plasma was transferred to eppindorf 
tubes (2-ml micro-centrifuge tube). 0.25 ml of 
plasma was taken and analyzed for 
haloperidol concentrations using the HPLC 
method described above. 
Transdermal application of the gel 
formulation
The same rabbits receiving The I. V. 
were used for determination of the plasma 
level-time profiles following transdermal 
administration dose after washout period of 
one month prior to the application of the dose.  
The hair was removed from the back of the 
rabbits (28.28cm
2
) with animal clipper 24 
hours before application of the gel. The skin 
was examined with a high power magnifying 
lens after shaving. The animal in which the 
skin barrier was disrupted or has scars or skin 
irritations was excluded from the study. The 
rabbits were immobilized in a restraining box 
during the entire experiments to prevent the 
animal from removing the gel. An area of 
5.033 cm
2
 was marked with a marker pen on 
the shaved area. A dose of 7.5 mg of 
haloperidol was spread uniformly over the 
designated area of each rabbit. Blood samples 
2.0 ml each were collected from the central 
artery via a catheter (18 x 1¼ inch) at the 
following time intervals 0, 1, 2, 3, 4, 6, 8, 10, 
12, 24, and 30 hours post application and 
processed for the assay of haloperidol as 
described before.
Oral Administration
The same 5 rabbits, which received 
the intravenous dose, were used after 1-month 
washout and rest period for the oral study. 
The animals were fasted for 18 hours before 
and during the experiment but were allowed 
to water. Before the animals were 
immobilized in a rabbit restrainer the tablet 5 
mg was administered by pushing the tablet 
after depressing the tongue (forced 
swallowing) followed by 8-10 ml water via a 
gastric tube. After receiving the dose the 
animals were immobilized in restrainers 
during sampling time. The central artery of 
the right ear was cannulated with i.v. catheter 
(18 G x 1¼ inch) for blood sampling. Blood 
samples, 1.5-2.0 ml each, were collected just 
prior to haloperidol administration and at 0, 
0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10 and 
12.0 hours post drug administration. The 
plasma was then separated after 
centrifugation, collected and stored frozen at -
20 
o
 C pending analysis.   
Before administration of the dose each 
rabbit was injected with 3000 units of heparin 
via marginal vein to avoid cannular occlusion 
at the sampling time. Blood samples, 1.5 ml 
each, were collected in 5ml heparinized 
evacuated blood collection tubes via iv-
catheter (18G X 1¼ inch) inserted into the 
central artery. Blood samples were 
centrifuged immediately for 10 minutes at 
4000 rpm and plasma were separated by using 
Pasteur pipettes and transferred to Bijue 
bottles and stored at – 20 
 o
 C before analysis. 
0.25 ml plasma was transferred to eppendorf 
tubes (2-ml-micro centrifuge tube) which 
were centrifuged at 13000 rpm for 5 minutes 
after addition of acetonitrile using 
microcentrifuge to precipitate the proteins.  
200-250 µl was then injected into a 50 µl 
loop, into the chromatogram and assayed for 
haloperidol.
Pharmacokinetic and statistical analysis
Pharmacokinetic parameters of 
haloperidol
 The plasma concentrations following 
intravenous administration of the drug were 
analyzed by a linear two compartment 
pharmacokinetic model using PKA analyst 
(Micro, Math Salt Lake city UT). The plasma 
concentration of haloperidol (Cp) as a 
function of time (t) was described by the 
following bi-exponential equation fitted in a 
two-compartment model.Cp = A e
-αt
 + B e
-βt
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Where: Cp is the drug concentration in the 
blood. A, B, are the exponential multipliers α, 
β denote hybrid rate constants in the 
compartment 1 and 2 respectively. The 






), the area under the plasma-
concentration time curve (AUC
o-∞
), the area 
under the first moment curve (AUMC
o-∞
), and 
the mean residence time of the drug in the 
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parameters for haloperidol following oral and 
transdermal administration were determined 
from the plasma concentration time data. The 
maximum plasma concentration (C
max
) and its 
corresponding time (T
max
) were obtained 
directly from the plasma concentration- time 
data. The area under the plasma 
concentration-time curve up to the last 
measurable plasma concentration (AUC
o-t
) 
and the area under the first moment curve 
(AUMC
o-t
) were estimated by linear 
trapezoidal rule and extrapolated to infinity 

























 is the last measurable 
concentration at time t. 
K
el
   is the terminal elimination rate 
constant calculated by the technique of the 
least-squares regression analysis.
The elimination half-life (t½) was calculated 





The mean residence time of the drug 





The mean absorption time (MAT) and the 
absolute bioavailability (F) of the oral tablet 
and the transdermal gel formulation were 
calculated using the following equations
11
: 
a. After oral administration:
     MAT = MRTpo- MRT
iv








    x Dose 
(oral).
 b. After transdermal application:  

















 is the mean residence time 
after oral administration, MRT
I.V.  
is the mean 
residence time after intravenous 
administration and MRT
TS
 is the mean 
residence time after transdermal 
administration. 
Statistical analysis
For comparative bioavailability study, plasma 










AUC, and AUMC were evaluated.  
Two compartmental pharmacokinetic 
model analysis were employed to estimate the 
pharmacokinetic parameters of intravenous 
dose, while pharmacokinetic parameters of 
oral and transdermal dosage were estimated 
using non-compartmental model.
The pharmacokinetic parameters of 
haloperidol calculated following oral and 
transdermal administration were evaluated 
statistically using one-way ANOVA. 
Differences between two related parameters 
were considered statistically significant for p 
< 0.05.
Results
In-vivo formulation studies 
Intravenous administration
 After intravenous bolus administration the 
plasma level concentrations time-curves of 
haloperidol versus time for individual rabbits 
and the mean plasma level of the 5 rabbits 
were shown in figure 1. Haloperidol was 
eliminated from the blood in biphasic pattern. 
A rabid and large decline in plasma curve was 
observed during the α-phase with average 
plasma concentration declined from206.9 
ng/ml after 10 minutes to74.56 ng/ml after 45 
minutes. 
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Figure: 1 Mean plasma concentration of 
haloperidol (ng/ml) after intravenous 
administration of 2.5mg dose 
And then declined slowly during the beta 
phase after 4 hours in 5 animals the plasma 
concentration ranged between 21.5-33.5ng/ml 
and then declined slowly till reached 
6.60ng/ml in 10 hours. Based on this data the 
deposition of haloperidol following 
intravenous dose could be adequately 
described by first order compartment model 
with first order rates in rabbits.
The mean pharmacokinetic parameters 





residence time (MRT), total clearance and 
steady state volume of distribution were 
summarized in table 1.
Table: 1 Mean pharmacokinetic parameters of haloperidol and the absolute bioavailability after oral 
and transdermal administration to five rabbits and the results of statistical analysis
Parameters Transdermal Oral P -Value









77.9 ± 4.50 92.26 ± 10.19 < 0.05 (S)
Tmax
(hr)
3.60 ± 0.89 1.60 ± 0.22 < 0.05 (S)
Kel
(1/hr)




10.91 ± 4.16 3.56 ± 0.4 < 0.05 (S)
Cmax/AUC0-
∞
















20.13 ± 6.17 57.70 ± 0.55 < 0.05 (S)
V
d
 (ml/Kg) 393.76 ± 129.44 359.70 ± 71.10 > 0.05 (NS)
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Oral tablet administration:
The data after this dose were 
represented in figures 2, the mean of the 
plasma concentration of 5 rabbits clearly 






























Figure: 2 Average plasma concentration-time 
profiles after application of oral and 
transdermal dosages of haloperidol to 5 
rabbits
The absorption of haloperidol was rapid with 
peak plasma concentration of 89.42 ng/ml 
observed after mean o f 1.5 hour post dosing. 
The pharmacokinetic parameters calculated 
after this dose were presented in table 2.
Table: 2 Mean pharmacokinetic parameters of 
Haloperidol after intravenous administration 
of 2.5mg dose.
*Mean of 5rabbits   
Transdermal administration
The data of average plasma 
concentrations following oral tablets and after 
transdermal administration of 7.5 mg gel 
formulation of haloperidol containing 1,8-
cineole as an enhancer were  shown in figure 
2. After application of trasdermal dose the 
plasma haloperidol concentration rose slowly 
to reach a peak after 2-4 hours with mean of 3 
hours then declined very slowly and sustained 
at steady state in all animals for 10-12 hours. 
Then the drug concentration remained 
constant at steady state pattern till the end of 
experiment. The pharmacokinetic generated 
from this data after the application of 
transdermal gel formulation were illustrated 
in table 2.
The mean pharmacokinetic parameters 
of haloperidol and the absolute bioavilability 
after oral and transdermal administrations to 
five rabbits and the results of Statistical 
Analysis were summarized in table 2.
Discussion
Intravenous administration 
The plasma concentration of haloperidol was 
known to follow two compartments 
distribution pattern with linear 
pharmacokinetics. The plasma concentration 
could be observed as follows;




The terminal half life was 4.20 hours which is 
close to that shown in rabbits after 
administration of the oral and application of 
transdermal dosage forms of haloperidol. 
Haloperidol could be measured in all samples, 
and the concentration of haloperidol was 
close to the limit of detection at the last 
sampling time, (12 hours for oral and 30 
hours for transdermal samples).
Although subject to some individual 
variation, the plasma concentration curves of 
haloperidol for the two preparations oral and 
transdermal, in all animals had the same 
general appearance (Figure 2) 
After application of both oral tablet 
and transdermal formulation the peak plasma 
concentration of haloperidol tablet was faster, 
reaching a peak plasma concentration in 1.6 
hours, than that observed for the transdermal 
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formulation which reached the peak in 3.60 
hours. This is due to higher rate of absorption 
of the tablet than that of the transdermal as the 
last preparation needs to cross the barrier 
property of the skin, and the tablet becomes 
immediately available for absorption. In 
addition the plasma levels of haloperidol were 
detectable for 30 hours for the transdermal 
formulation   and this may indicate 
maintenance of haloperidol plasma levels for 
longer time.
Since the area under plasma 
concentration is the measure of the amount of 
the drug absorbed into the circulation
12





were calculated for the two 
preparations (Table 2). These data in table 2 
clearly showed that the mean    AUC 
0-∞
 after 
transdermal preparation was significantly 
higher than that obtained after tablet dosage 
form (p < 0.05). The increase in the amount of 
drug absorbed was thus associated with the 
increase of peak blood levels; this was further 
confirmed by linear regression analysis 
showing a good correlation between 




The absolute bioavailability of the 
transdermal dosage form [57.8%] was 
significantly higher than the oral dosage form 
level [38.1%] (P < 0.05). This may be due to 
the fact that transdermal administration could 
at least partially avoid the liver first pass 
effect. The relative bioavailability of 
transdermal to the oral tablet was 150%. The 
transdermal formulation was also 
characterized by an increase of elimination 
half-life and decrease in elimination rate 
constant and a decrease in absorption rate 
compared to the oral tablet (Table 2). This 
data clearly shows a flip-flop phenomenon, 
which is well documented in the literature
13
. 
This phenomenon is often associated with 
sustained release formulation where 
absorption of drug from the formulation 
associated with apparent increase in 
elimination half-life and decreases in 
elimination rate constant and therefore, over 
estimation of rate constant may lead to over 
estimation of area under the curve. 
Comparing the peak plasma concentration of 
haloperidol after oral and transdermal, which 
were 92.26 and 77.9 ng/ml respectively, 
shows statistical difference between them (p < 
o.o5).
 Comparing the T
max
 for the two preparations 
indicated that a shift in time for the maximum 
blood concentration 1.60 hours for oral tablet 
and 4.60 hours for transdermal formulation. 
The T
max
 is one of the parameters taken for 
the measure of the drug absorption rate and it 
gives a good indication of sustained 
formulation.
Another indication of prolonged drug 
delivery of haloperidol transdermal 
formulation is higher mean residence time 





. The ratio of C
max
/AUC was 
shown to be a good parameter and preferred 
to C
max
 for evaluation rates of absorption of 
single dose prolonged preparations
14, 15.
Moreover the, the ratio tends to have smaller 
variations and strongly recommended for 




The MRT was significantly higher after 
transdermal application and absorption rate 
was significantly lower for transdermal 
preparation. The MRT and MAT were shown 
to be good parameters for describing the 
pharmacokinetic behavior of drug in the body 
after oral and sustained preparations
17, 10
. The 
MRT and MAT were dramatically increased 
after application of transdermal formulation 
compared to the oral tablet. The delayed in 
absorption of the drug [longer T
max
] following 
the transdermal application could explain the 
increase of the MRT obtained after 
application of transdermal application of 
haloperidol dosage compared to that of the 
oral tablet. The volume of distribution and 
systemic clearance were higher after 
application of transdermal application 
preparations indicating that the increase in the 
MRT is due to delayed absorption of 
haloperidol. 
Abubakr S. Elgorashi                                             Bioavailability of Transdermal Haloperidol
© Sudan JMS Vol. 4, No. 1, Mar.2009                   54
Conclusion
  In conclusion, the transdermal 
haloperidol gel formulation produced 
acceptable sustained plasma drug 
concentration for longer time with an increase 
of extent of absorption and longer residence 
time of drug in a constant therapeutic blood 
level without the danger of dose dumping 
effect seen in the oral tablet. The study 
revealed that haloperidol/ hydroxypropyl 
methyl cellulose gel formulation containing 
1,8-cineole exhibited acceptable gel 
consistency required for transdermal 
formulation and was readily spread when 
applied to the skin and remained on the skin 
to provide continuous drug absorption. This 
formulation could be used for further human 
clinical studies to produce effective and 
clinically acceptable transdermal formulation. 
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